Gilead Sciences (NASDAQ:GILD) Price Target Raised to $145.00

Gilead Sciences (NASDAQ:GILD) had its price objective lifted by JPMorgan Chase & Co. from $135.00 to $145.00 in a report released on Tuesday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently commented on GILD. UBS Group boosted their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research report on Friday, July 25th. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a research report on Tuesday, August 19th. Finally, Royal Bank Of Canada boosted their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research report on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.17.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $113.62 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $140.98 billion, a P/E ratio of 22.63, a P/E/G ratio of 0.76 and a beta of 0.36. Gilead Sciences has a 12 month low of $81.83 and a 12 month high of $121.83. The business’s 50-day moving average is $114.01 and its 200 day moving average is $110.07.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences’s dividend payout ratio is 62.95%.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the completion of the transaction, the chief financial officer directly owned 160,110 shares in the company, valued at approximately $18,977,838.30. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,390,030 in the last ninety days. 0.27% of the stock is owned by company insiders.

Institutional Trading of Gilead Sciences

A number of hedge funds have recently bought and sold shares of GILD. Brighton Jones LLC lifted its holdings in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the period. Bison Wealth LLC purchased a new stake in Gilead Sciences during the fourth quarter worth $215,000. Zurich Insurance Group Ltd FI lifted its holdings in Gilead Sciences by 232.1% during the fourth quarter. Zurich Insurance Group Ltd FI now owns 908,894 shares of the biopharmaceutical company’s stock worth $83,955,000 after buying an additional 635,209 shares during the period. Waverly Advisors LLC lifted its holdings in Gilead Sciences by 8.6% during the fourth quarter. Waverly Advisors LLC now owns 29,181 shares of the biopharmaceutical company’s stock worth $2,695,000 after buying an additional 2,320 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Gilead Sciences by 15.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,234,672 shares of the biopharmaceutical company’s stock worth $1,130,117,000 after buying an additional 1,605,730 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.